1. Rodriguez-Merchan EC, Forriol F. Nonunion: general principles and
experimental data. Clin Orthop Relat Res. 2004;419:4–12.
2. Hak DJ, Fitzpatrick D, Bishop JA, Marsh JL, Tilp S, Schnettler R, et al.
Delayed union and nonunions: epidemiology, clinical issues, and financial
aspects. Injury. 2014;45(Suppl 2):S3–7.
3. Niikura T, Lee SY, Sakai Y, Nishida K, Kuroda R, Kurosaka M. Causative
factors of fracture nonunion: the proportions of mechanical, biological, patient-dependent, and patient-independent factors. J Orthop Sci.
2014;19:120–4.
4. Dickson K, Katzman S, Delgado E, Contreras D. Delayed unions and nonunions of open tibial fractures. Correlation with arteriography results. Clin
Orthop Relat Res. 1994;302:189–93.
5. Lu C, Miclau T, Hu D, Marcucio RS. Ischemia leads to delayed union during
fracture healing: a mouse model. J Orthop Res. 2007;25:51–61.
6. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, et al.
Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment
of tibial nonunions. J Bone Joint Surg Am. 2001;83–A(2)(Suppl 1):S151–8.
7. Zimmermann G, Wagner C, Schmeckenbecher K, Wentzensen A,
Moghaddam A. Treatment of tibial shaft non-unions: bone morphogenetic proteins versus autologous bone graft. Injury. 2009;40(Suppl
3):S50–3.
8. Calori GM, Colombo M, Bucci M, Mazza EL, Fadigati P, Mazzola S. Clinical
effectiveness of Osigraft in long-bones non-unions. Injury. 2015;46(Suppl
8):S55–64.
9. Tressler MA, Richards JE, Sofianos D, Comrie FK, Kregor PJ, Obremskey
WT. Bone morphogenetic protein-2 compared to autologous iliac
crest bone graft in the treatment of long bone nonunion. Orthopedics.
2011;34:e877–84.
10. Takemoto R, Forman J, Taormina DP, Egol KA. No advantage to rhBMP-2
in addition to autogenous graft for fracture nonunion. Orthopedics.
2014;37:e525–30.
11. von Rüden C, Morgenstern M, Hierholzer C, Hackl S, Gradinger FL,
Woltmann A, et al. The missing effect of human recombinant bone
23. 24. 25. 26. 27. 28. 29. 30. morphogenetic proteins BMP-2 and BMP-7 in surgical treatment of
aseptic forearm nonunion. Injury. 2016;47:919–24.
von Rüden C, Morgenstern M, Friederichs J, Augat P, Hackl S, Woltmann
A, et al. Comparative study suggests that human bone morphogenetic
proteins have no influence on the outcome of operative treatment of
aseptic clavicle non-unions. Int Orthop. 2016;40:2339–45.
Hackl S, Hierholzer C, Friederichs J, Woltmann A, Bühren V, von Rüden
C. Long-term outcome following additional rhBMP-7 application in
revision surgery of aseptic humeral, femoral, and tibial shaft nonunion.
BMC Musculoskelet Disord. 2017;18:342.
Dimitriou R, Dahabreh Z, Katsoulis E, Matthews SJ, Branfoot T, Giannoudis PV. Application of recombinant BMP-7 on persistent upper and
lower limb non-unions. Injury. 2005;36(Suppl 4):S51–9.
Kanakaris NK, Lasanianos N, Calori GM, Verdonk R, Blokhuis TJ, Cherubino P, et al. Application of bone morphogenetic proteins to femoral
non-unions: a 4-year multicentre experience. Injury. 2009;40(Suppl
3):S54–61.
Moghaddam A, Elleser C, Biglari B, Wentzensen A, Zimmermann G.
Clinical application of BMP 7 in long bone non-unions. Arch Orthop
Trauma Surg. 2010;130:71–6.
Papanagiotou M, Dailiana ZH, Karachalios T, Varitimidis S, Vlychou M,
Hantes M, et al. RhBMP-7 for the treatment of nonunion of fractures of
long bones. Bone Joint J. 2015;97-B(7):997–1003.
Morison Z, Vicente M, Schemitsch EH, McKee MD. The treatment of
atrophic, recalcitrant long-bone nonunion in the upper extremity with
human recombinant bone morphogenetic protein-7 (rhBMP-7) and
plate fixation: a retrospective review. Injury. 2016;47:356–63.
Giannoudis PV, Tzioupis C. Clinical applications of BMP-7: the UK perspective. Injury. 2005;36(Suppl 3):S47–50.
Fuchs T, Stolberg-Stolberg J, Michel PA, Garcia P, Amler S, Wähnert D,
et al. Effect of bone morphogenetic protein-2 in the treatment of long
bone non-unions. J Clin Med. 2021;10:4597.
Conway JD, Shabtai L, Bauernschub A, Specht SC. BMP-7 versus
BMP-2 for the treatment of long bone nonunion. Orthopedics.
2014;37:e1049–57.
Haubruck P, Tanner MC, Vlachopoulos W, Hagelskamp S, Miska M, Ober J,
et al. Comparison of the clinical effectiveness of bone morphogenic protein (BMP) −2 and −7 in the adjunct treatment of lower limb nonunions.
Orthop Traumatol Surg Res. 2018;104:1241–8.
Hannemann PF, Mommers EHH, Schots JPM, Brink PRG, Poeze M. The
effects of low-intensity pulsed ultrasound and pulsed electromagnetic
fields bone growth stimulation in acute fractures: a systematic review
and meta-analysis of randomized controlled trials. Arch Orthop Trauma
Surg. 2014;134:1093–106.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science.
1997;275:964–7.
Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone
marrow origin of endothelial progenitor cells responsible for postnatal
vasculogenesis in physiological and pathological neovascularization. Circ
Res. 1999;85:221–8.
Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al.
Ischemia- and cytokine-induced mobilization of bone marrowderived endothelial progenitor cells for neovascularization. Nat Med.
1999;5:434–8.
Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin
M, et al. Intramyocardial transplantation of autologous CD34+ stem cells
for intractable angina: a phase I/IIa double-blind, randomized controlled
trial. Circulation. 2007;115:3165–72.
Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M,
et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in
patients with critical limb ischemia: a phase I/IIa, multicenter, singleblinded, dose-escalation clinical trial. Stem Cells. 2009;27:2857–64.
Fujita Y, Kinoshita M, Furukawa Y, Nagano T, Hashimoto H, Hirami Y, et al.
Phase II clinical trial of CD34+ cell therapy to explore endpoint selection
and timing in patients with critical limb ischemia. Circ J. 2014;78:490–501.
Ohtake T, Mochida Y, Ishioka K, Oka M, Maesato K, Moriya H, et al. Autologous granulocyte colony-stimulating factor-mobilized peripheral blood
CD34 positive cell transplantation for hemodialysis patients with critical
limb ischemia: a prospective Phase II clinical trial. Stem Cells Transl Med.
2018;7:774–82.
Kuroda et al. BMC Medicine
(2023) 21:386
31. Long MW, Williams JL, Mann KG. Expression of human bone-related
proteins in the hematopoietic microenvironment. J Clin Invest.
1990;86:1387–95.
32. Chen JL, Hunt P, McElvain M, Black T, Kaufman S, Choi ES. Osteoblast
precursor cells are found in CD34+ cells from human bone marrow. Stem
Cells. 1997;15:368–77.
33. Dominici M, Pritchard C, Garlits JE, Hofmann TJ, Persons DA, Horwitz EM.
Hematopoietic cells and osteoblasts are derived from a common marrow
progenitor after bone marrow transplantation. Proc Natl Acad Sci USA.
2004;101:11761–6.
34. Ford JL, Robinson DE, Scammell BE. Endochondral ossification in fracture
callus during long bone repair: the localisation of “cavity-lining cells”
within the cartilage. J Orthop Res. 2004;22:368–75.
35. Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, et al.
Mesenchymal stem cells derived from CD133-positive cells in mobilized
peripheral blood and cord blood: proliferation, Oct4 expression, and
plasticity. Stem Cells. 2005;23:1105–12.
36. Laing AJ, Dillon JP, Condon ET, Street JT, Wang JH, McGuinness AJ, et al.
Mobilization of endothelial precursor cells: systemic vascular response to
musculoskeletal trauma. J Orthop Res. 2007;25:44–50.
37. Matsumoto T, Mifune Y, Kawamoto A, Kuroda R, Shoji T, Iwasaki H, et al.
Fracture induced mobilization and incorporation of bone marrowderived endothelial progenitor cells for bone healing. J Cell Physiol.
2008;215:234–42.
38. Matsumoto T, Kawamoto A, Kuroda R, Ishikawa M, Mifune Y, Iwasaki
H, et al. Therapeutic potential of vasculogenesis and osteogenesis
promoted by peripheral blood CD34-positive cells for functional bone
healing. Am J Pathol. 2006;169:1440–57.
39. Mifune Y, Matsumoto T, Kawamoto A, Kuroda R, Shoji T, Iwasaki H, et al.
Local delivery of granulocyte colony stimulating factor-mobilized CD34positive progenitor cells using bioscaffold for modality of unhealing
bone fracture. Stem Cells. 2008;26:1395–405.
40. Fukui T, Mifune Y, Matsumoto T, Shoji T, Kawakami Y, Kawamoto A, et al.
Superior potential of CD34-positive cells compared to total mononuclear
cells for healing of nonunion following bone fracture. Cell Transplant.
2015;24:1379–93.
41. Kuroda R, Matsumoto T, Niikura T, Kawakami Y, Fukui T, Lee SY, et al. Local
transplantation of granulocyte colony stimulating factor-mobilized
CD34+ cells for patients with femoral and tibial nonunion: pilot clinical
trial. Stem Cells Transl Med. 2014;3:128–34.
42. Fukuda M. Classification and treatment of diabetic retinopathy. Diabetes
Res Clin Pract. 1994;24 Suppl:S171–6.
43. Meinberg EG, Agel J, Roberts CS, Karam MD, Kellam JF. Fracture and dislocation classification compendium-2018. J Orthop Trauma. 2018;32(Suppl
1):S1–170.
44. Vannabouathong C, Sprague S, Bhandari M. Guidelines for fracture healing assessments in clinical trials. Part I: definitions and endpoint committees. Injury. 2011;42:314–6.
45. Kooistra BW, Dijkman BG, Busse JW, Sprague S, Schemitsch EH, Bhandari
M. The radiographic union scale in tibial fractures: reliability and validity. J
Orthop Trauma. 2010;24(Suppl 1):S81–6.
46. Chiavaras MM, Bains S, Choudur H, Parasu N, Jacobson J, Ayeni O, et al.
The radiographic union score for hip (RUSH): the use of a checklist to
evaluate hip fracture healing improves agreement between radiologists
and orthopedic surgeons. Skelet Radiol. 2013;42:1079–88.
47. Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T,
et al. Validating the SF-36 health survey questionnaire: new outcome
measure for primary care. BMJ. 1992;305:160–4.
48. Johanson NA, Liang MH, Daltroy L, Rudicel S, Richmond J. American
Academy of Orthopaedic Surgeons lower limb outcomes assessment
instruments. Reliability, validity, and sensitivity to change. J Bone Joint
Surg Am. 2004;86:902–9.
49. Japanese Society of Chemotherapy, Antimicrobial Agents Safety Evaluation Standards Committee, Watanabe A, Tokue Y, Aoki N, Matsumoto
T, et al. Criteria for safety evaluation of antimicrobial agents. J Infect
Chemother. 2011;17:139–47.
50. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous
bone-marrow grafting for nonunions. Influence of the number and
concentration of progenitor cells. J Bone Joint Surg Am. 2005;87:1430–7.
Page 16 of 16
51. Singh AK, Shetty S, Saraswathy JJ, Sinha A. Percutaneous autologous
bone marrow injections for delayed or non-union of bones. J Orthop
Surg (Hong Kong). 2013;21:60–4.
52. Sugaya H, Mishima H, Aoto K, Li M, Shimizu Y, Yoshioka T, et al. Percutaneous autologous concentrated bone marrow grafting in the treatment for
nonunion. Eur J Orthop Surg Traumatol. 2014;24:671–8.
53. Ismail HD, Phedy P, Kholinne E, Djaja YP, Kusnadi Y, Merlina M, et al. Mesenchymal stem cell implantation in atrophic nonunion of the long bones: a
translational study. Bone Joint Res. 2016;5:287–93.
54. Gómez-Barrena E, Padilla-Eguiluz N, Rosset P, Gebhard F, Hernigou P,
Baldini N, et al. Early efficacy evaluation of mesenchymal stromal cells
(MSC) combined to biomaterials to treat long bone non-unions. Injury.
2020;51(Suppl 1):S63–73.
55. Wang X, Chu W, Zhuang Y, Shi D, Tao H, Jin C, et al. Bone mesenchymal
stem cell-enriched β-tricalcium phosphate scaffold processed by the
screen-enrich-combine circulating system promotes regeneration of
diaphyseal bone non-union. Cell Transplant. 2019;28:212–23.
56. Gómez-Barrena E, Rosset P, Gebhard F, Hernigou P, Baldini N, Rouard H,
et al. Feasibility and safety of treating non-unions in tibia, femur and
humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. Biomaterials. 2019;196:100–8.
57. Dufrane D, Docquier PL, Delloye C, Poirel HA, André W, Aouassar N.
Scaffold-free three-dimensional graft from autologous adipose-derived
stem cells for large bone defect reconstruction: clinical proof of concept.
Medicine. 2015;94:e2220.
58. Giannoudis PV, Gudipati S, Harwood P, Kanakaris NK. Long bone nonunions treated with the diamond concept: a case series of 64 patients.
Injury. 2015;46 Suppl 8:S48–54.
59. Ishida K, Matsumoto T, Sasaki K, Mifune Y, Tei K, Kubo S, et al. Bone
regeneration properties of granulocyte colony-stimulating factor via
neovascularization and osteogenesis. Tissue Eng Part A. 2010;16:3271–84.
60. Moukoko D, Pourquier D, Genovesio C, Thezenas S, Chabrand P, Roffino
S, et al. Granulocyte-colony stimulating factor enhances bone fracture
healing. Clin Biomech (Bristol Avon). 2018;58:62–8.
61. Kurniawan A, Kodrat E, Gani YI. Effectiveness of granulocyte colony
stimulating factor to enhance healing on delayed union fracture model
Sprague-Dawley rat. Ann Med Surg (Lond). 2021;61:54–60.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ready to submit your research ? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
...
論文の公開元へ
